vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Genius Sports Ltd (GENI). Click either name above to swap in a different company.
Genius Sports Ltd is the larger business by last-quarter revenue ($510.9M vs $284.0M, roughly 1.8× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -12.3%, a 108.7% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.
ACAD vs GENI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $510.9M |
| Net Profit | $273.6M | $-63.0M |
| Gross Margin | 90.8% | 25.2% |
| Operating Margin | 6.1% | -11.5% |
| Net Margin | 96.3% | -12.3% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $510.9M | ||
| Q3 25 | $278.6M | $335.4M | ||
| Q2 25 | $264.6M | $215.2M | ||
| Q1 25 | $244.3M | $119.7M | ||
| Q4 24 | $259.6M | $413.0M | ||
| Q3 24 | $250.4M | $285.8M | ||
| Q2 24 | $242.0M | $184.1M | ||
| Q1 24 | $205.8M | $97.2M |
| Q4 25 | $273.6M | $-63.0M | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $26.7M | $-47.3M | ||
| Q1 25 | $19.0M | $-25.5M | ||
| Q4 24 | $143.7M | $-85.5M | ||
| Q3 24 | $32.8M | $-47.1M | ||
| Q2 24 | $33.4M | $-35.5M | ||
| Q1 24 | $16.6M | $-25.2M |
| Q4 25 | 90.8% | 25.2% | ||
| Q3 25 | 92.2% | 24.2% | ||
| Q2 25 | 92.2% | 19.1% | ||
| Q1 25 | 91.7% | 10.7% | ||
| Q4 24 | 91.6% | 16.7% | ||
| Q3 24 | 92.5% | 20.5% | ||
| Q2 24 | 92.5% | 18.6% | ||
| Q1 24 | 88.8% | 9.8% |
| Q4 25 | 6.1% | -11.5% | ||
| Q3 25 | 12.8% | -15.3% | ||
| Q2 25 | 12.2% | -21.0% | ||
| Q1 25 | 7.9% | -20.3% | ||
| Q4 24 | 59.1% | -18.0% | ||
| Q3 24 | 12.6% | -13.9% | ||
| Q2 24 | 12.6% | -16.8% | ||
| Q1 24 | 7.4% | -23.7% |
| Q4 25 | 96.3% | -12.3% | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 10.1% | -22.0% | ||
| Q1 25 | 7.8% | -21.3% | ||
| Q4 24 | 55.4% | -20.7% | ||
| Q3 24 | 13.1% | -16.5% | ||
| Q2 24 | 13.8% | -19.3% | ||
| Q1 24 | 8.0% | -25.9% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $280.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $724.5M |
| Total Assets | $1.6B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $280.6M | ||
| Q3 25 | $258.0M | $110.2M | ||
| Q2 25 | $253.6M | $110.2M | ||
| Q1 25 | $217.7M | $110.2M | ||
| Q4 24 | $319.6M | $100.3M | ||
| Q3 24 | $155.1M | $100.3M | ||
| Q2 24 | $177.1M | $100.3M | ||
| Q1 24 | $204.7M | $100.3M |
| Q4 25 | $1.2B | $724.5M | ||
| Q3 25 | $917.3M | $572.4M | ||
| Q2 25 | $822.4M | $572.4M | ||
| Q1 25 | $765.2M | $572.4M | ||
| Q4 24 | $732.8M | $573.0M | ||
| Q3 24 | $577.2M | $573.0M | ||
| Q2 24 | $516.7M | $573.0M | ||
| Q1 24 | $464.0M | $573.0M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.3B | $792.3M | ||
| Q2 25 | $1.2B | $792.3M | ||
| Q1 25 | $1.1B | $792.3M | ||
| Q4 24 | $1.2B | $775.7M | ||
| Q3 24 | $976.9M | $775.7M | ||
| Q2 24 | $914.1M | $775.7M | ||
| Q1 24 | $855.1M | $775.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $81.9M |
| Free Cash FlowOCF − Capex | — | $69.6M |
| FCF MarginFCF / Revenue | — | 13.6% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $33.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $81.9M | ||
| Q3 25 | $74.3M | $-4.8M | ||
| Q2 25 | $64.0M | $-1.2M | ||
| Q1 25 | $20.3M | $-14.6M | ||
| Q4 24 | $40.4M | $14.9M | ||
| Q3 24 | $63.2M | $-9.2M | ||
| Q2 24 | $25.0M | — | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | $69.6M | ||
| Q3 25 | $73.9M | $-14.2M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $11.3M | ||
| Q3 24 | $63.2M | $-11.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 13.6% | ||
| Q3 25 | 26.5% | -4.2% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | -13.4% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | 25.2% | -4.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
GENI
Segment breakdown not available.
